Transcatheter arterial chemoembolization with anticancer drug in iodized oil for primary hepatic carcinoma

1989 ◽  
Vol 12 (4) ◽  
pp. 181-187 ◽  
Author(s):  
Junyuan Guo ◽  
Dong Yen ◽  
Zhizheng Huang ◽  
Guodong Hu ◽  
Pencheng Liu
Keyword(s):  
Anticancer Drug ◽  
Transcatheter Arterial Chemoembolization ◽  
Hepatic Carcinoma ◽  
Iodized Oil ◽  
Primary Hepatic Carcinoma ◽  
Arterial Chemoembolization

scholarly journals Efficacy and Safety of Aidi Injection Combined with Transcatheter Arterial Chemoembolization on Primary Hepatic Carcinoma: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-14
Author(s):  
Weihao Chen ◽  
Yurong Wang ◽  
Qiuer Liang ◽  
Yunfei Cai ◽  
Xudong Chen ◽  
...  
Keyword(s):  
Clinical Response ◽  
Transcatheter Arterial Chemoembolization ◽  
Response Rate ◽  
Clinical Response Rate ◽  
Efficacy And Safety ◽  
Hepatic Carcinoma ◽  
Primary Hepatic Carcinoma ◽  
Significant Difference ◽  
Aidi Injection ◽  
Arterial Chemoembolization

Objectives. To evaluate the efficacy and safety of Aidi injection (ADI) combined with transcatheter arterial chemoembolization (TACE) for primary hepatic carcinoma (PHCC). Methods. We conducted a literature search in EMBASE, PubMed, CENTRAL, MEDLINE, CNKI, Wanfang, and VIP databases from the earliest possible year to April 2018. Randomized controlled trials (RCTs) involving ADI combined with TACE versus TACE alone for patients with PHCC were included. The Cochrane Risk of Bias tool was applied for quality assessment. Results. 22 studies involving 1611 participants were included. The clinical response rate (RR = 1.28, 95% CI: 1.17-1.40; P < 0.00001), KPS score (RR = 1.78, 95% CI: 1.59-2.00; P < 0.00001), survival rate (RR = 1.27, 95% CI: 1.16-1.39; P < 0.00001), immune function (MD = 1.24, 95% CI: 0.98-1.51; P < 0.00001), and adverse effects (RR = 0.62, 95% CI: 0.57-0.68; P < 0.00001) of ADI plus TACE showed significant difference when compared with TACE alone. Conclusions. ADI combined with TACE in the treatment of PHCC improved the clinical response rate and safety compared to TACE alone. However, due to poor methodological quality of many of the included RCTs, more rigorously designed and large-scale RCTs are warranted to examine this beneficial effect in the future.

scholarly journals Effect of iodized oil embolization on ablation rates in primary hepatic carcinoma

2015 ◽  
Vol 23 (36) ◽  
pp. 5859
Author(s):  
Xing-Wei Sun ◽  
Yong Jin ◽  
Xu-Ming Bai ◽  
Long Cheng ◽  
Xing-Shi Gu ◽  
...  
Keyword(s):  
Hepatic Carcinoma ◽  
Iodized Oil ◽  
Primary Hepatic Carcinoma

Study of the role of transcatheter arterial chemoembolization using iodized oil with and without gel foam for the management of hepatocellular carcinoma

2015 ◽  
Vol 28 (2) ◽  
pp. 447
Author(s):  
AymanAbd El-Halim Mohammed El-Gamal ◽  
HanySaid Sabry ◽  
UsamaaLotfy El-Abd ◽  
GamalSaad El Deeb ◽  
AymanMohamed El-Lehleh
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transcatheter Arterial Chemoembolization ◽  
Iodized Oil ◽  
Arterial Chemoembolization

Predictive factors of transcatheter arterial chemoembolization for hepatocellular carcinoma

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4541-4541
Author(s):  
H. Ishii ◽  
J. Furuse ◽  
K. Nakachi ◽  
E. Suzuki ◽  
S. Shimizu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Predictive Factors ◽  
Transcatheter Arterial Chemoembolization ◽  
Objective Response ◽  
Gelatin Sponge ◽  
Iodized Oil ◽  
Multiple Tumors ◽  
Multiple Tumor ◽  
Solitary Tumor ◽  
Arterial Chemoembolization

4541 Background/Aim: Although transcatheter arterial chemoembolization (TACE) has been widely used for the treatment of unresectable hepatocellular carcinoma (HCC), the optimal indication of the TACE has not been fully elucidated. Methods: The treatment outcomes after TACE were analyzed retrospectively to determine predictive factors of anti-cancer effect on HCC. The patient (pts) selection criteria were: 1) admission between 1992 and 2005, 2) diagnosis of fresh HCC, 3) no extrahepatic metastasis and 4) primary treatment with TACE. TACE was performed by selectively introducing a catheter into the hepatic artery and injecting gelatin sponge particles following an emulsion consisting of 2–5 ml of iodized oil (Lipiodol) and 20–50 mg doxorubicin hydrochloride. Lipiodol accumulation in tumors was regarded as an indication of necrosis. We defined complete response (CR) as disappearance or 100% necrosis of all tumors, and partial response (PR) as more than 50% reduction and/or more than 50% necrosis. Results: There were 270 pts who fulfilled the above criteria. According to Japan Integrated Staging, the number of T1, T2, T3 and T4 was 10, 59, 171 and 30, respectively. There were 52 CRs, 113 PRs, 77 who remained SD and 28 who showed PD/NE. The median survival months of CR, PR, SD and PD/NE were 50, 30, 15 and 5, respectively, and there was a significant differences between them. The logistic regression analysis revealed tumor multiplicity and vascular invasion (VI) were significantly associated with the objective response (CR or PR). The response probability of patients with solitary tumor without VI was 85%, that with multiple tumors without VI was 63%, that with solitary tumor with VI was 33% and that with multiple tumors with VI was 16%. The small tumor (<5 cm) was another favorable factor which was significantly associated with CR. Among 231 patients without VI, the CR probability of patients with a solitary tumor <5 cm or >5 cm was 46% or 40%, respectively; although that of those with multiple tumors <5cm or >5cm was 21% or 5%, respectively. Conclusion: TACE is recommended for HCC patients without VI, and is optimally indicated for those with a solitary tumor or those with multiple tumor <5 cm among them. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document